ArticleBreast (Edinburgh, Scotland)2022

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC.

Shuyue Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.